Geron Shares Drop After Wider-Than-Expected 4Q Loss

Dow Jones

Feb 27

By Chris Wack

Geron shares fell 30% to $1.66 after the company reported a fourth-quarter loss that was wider than expected.

The biopharmaceutical company had a quarterly loss of $25.4 million, or 4 cents a share, compared with a loss of $52 million, or 9 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $12 million, or 2 cents a share.

Revenue for the quarter was $47.5 million, compared with last year's $23,000 and the $61.8 million analysts were expecting.

Geron expects to reach profitability without additional financing if current internal sales and operating expenses expectations are met. The company launched Rytelo, a telomerase inhibitor, at the end of June.

Geron had $502.9 million in cash and cash equivalents at Dec. 31.

For fiscal 2025, the company is looking for total operating expenses to be $270 million to $285 million.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

February 26, 2025 13:11 ET (18:11 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2514866346"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514866346\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514866346?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 02:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514866346","market":"nz","top_or_hot":-1,"title":"Geron Shares Drop After Wider-Than-Expected 4Q Loss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Geron shares fell 30% to $1.66 after the company reported a fourth-quarter loss that was wider than expected. \n</p>\n<p>\n  The biopharmaceutical company had a quarterly loss of $25.4 million, or 4 cents a share, compared with a loss of $52 million, or 9 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $12 million, or 2 cents a share. \n</p>\n<p>\n  Revenue for the quarter was $47.5 million, compared with last year's $23,000 and the $61.8 million analysts were expecting. \n</p>\n<p>\n  Geron expects to reach profitability without additional financing if current internal sales and operating expenses expectations are met. The company launched Rytelo, a telomerase inhibitor, at the end of June. \n</p>\n<p>\n  Geron had $502.9 million in cash and cash equivalents at Dec. 31. \n</p>\n<p>\n  For fiscal 2025, the company is looking for total operating expenses to be $270 million to $285 million. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 26, 2025 13:11 ET (18:11 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Geron Shares Drop After Wider-Than-Expected 4Q Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGeron Shares Drop After Wider-Than-Expected 4Q Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-27 02:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Geron shares fell 30% to $1.66 after the company reported a fourth-quarter loss that was wider than expected. \n</p>\n<p>\n  The biopharmaceutical company had a quarterly loss of $25.4 million, or 4 cents a share, compared with a loss of $52 million, or 9 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $12 million, or 2 cents a share. \n</p>\n<p>\n  Revenue for the quarter was $47.5 million, compared with last year's $23,000 and the $61.8 million analysts were expecting. \n</p>\n<p>\n  Geron expects to reach profitability without additional financing if current internal sales and operating expenses expectations are met. The company launched Rytelo, a telomerase inhibitor, at the end of June. \n</p>\n<p>\n  Geron had $502.9 million in cash and cash equivalents at Dec. 31. \n</p>\n<p>\n  For fiscal 2025, the company is looking for total operating expenses to be $270 million to $285 million. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 26, 2025 13:11 ET (18:11 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GERN","symbol_name":"杰龙","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2514866346","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514866346","pubTimestamp":1740593460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Geron shares fell 30% to $1.66 after the company reported a fourth-quarter loss that was wider than expected.The biopharmaceutical company had a quarterly loss of $25.4 million, or 4 cents a share, compared with a loss of $52 million, or 9 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $12 million, or 2 cents a share.Revenue for the quarter was $47.5 million, compared with last year's $23,000 and the $61.8 million analysts were expecting.Geron expects to reach profitability without additional financing if current internal sales and operating expenses expectations are met. The company launched Rytelo, a telomerase inhibitor, at the end of June.Geron had $502.9 million in cash and cash equivalents at Dec. 31.For fiscal 2025, the company is looking for total operating expenses to be $270 million to $285 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GERN":"杰龙","BK4139":"生物科技"},"translate_title":"Geron第四季度亏损超出预期后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GERN":1},"content_text":"By Chris Wack \n\n\n \n\n\n  Geron shares fell 30% to $1.66 after the company reported a fourth-quarter loss that was wider than expected. \n\n\n  The biopharmaceutical company had a quarterly loss of $25.4 million, or 4 cents a share, compared with a loss of $52 million, or 9 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $12 million, or 2 cents a share. \n\n\n  Revenue for the quarter was $47.5 million, compared with last year's $23,000 and the $61.8 million analysts were expecting. \n\n\n  Geron expects to reach profitability without additional financing if current internal sales and operating expenses expectations are met. The company launched Rytelo, a telomerase inhibitor, at the end of June. \n\n\n  Geron had $502.9 million in cash and cash equivalents at Dec. 31. \n\n\n  For fiscal 2025, the company is looking for total operating expenses to be $270 million to $285 million. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2025 13:11 ET (18:11 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}